Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

GTx To File NDA For Acapodene In Early 2008

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Phase III interim analysis finds the selective estrogen receptor modulator lowers cholesterol associated with androgen deprivation therapy for prostate cancer.

You may also be interested in...



GTx Closer To Filing NDA For Acapodene With Promising Phase III Results

Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.

GTx Closer To Filing NDA For Acapodene With Promising Phase III Results

Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.

GTx Phase IIIb Study Will Evaluate Therapy For Prostate Cancer Treatment Side Effects

GTx is initiating an extension of its Phase III clinical trial of Acapodene in prostate cancer patients.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS064371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By